OSRH Stock — OSR Holdings Inc

OSR Holdings Inc (OSRH)

Updated October 16, 2026.

OSRH is a Stock. Total return is -97.8% over the past 3.6 years, 202.2 points behind SPY at 104.4%.

OSR Health is a healthcare holding company developing immunotherapy products for cancer treatment, including the clinical-stage candidate VXM01 for glioblastoma and several preclinical immuno-oncology programs, alongside design-augmented biologics for orthopedic applications and a neurovascular medical device distribution business. The company does not currently distribute dividends to shareholders. OSR Health appeals primarily to growth-oriented investors seeking exposure to early-stage clinical-stage immunotherapy development rather than current income.

OSRH performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.8% over the past 3.6 years, 202.2 points behind SPY at 104.4%. Over the past year its total return — price change plus distributions reinvested — is -60.7%. Its deepest 1-year drawdown was 85.7%.

OSRH key facts

Asset type

Stock

Asset class

Equity

Inception date

03/17/2023

Distribution frequency

None

Last close

$0.22 (as of 2026-10-16)

Market cap

$7,726,112

Average volume

151188.0

Beta

0.482

Payout ratio

0.0%

EPS

$-0.37

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

OSRH risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 85.7%.

Who may consider OSRH — and who may not

It is a weaker fit for investors who need monthly cash flow (OSRH does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on OSRH

• All tickers starting with O

Tagged: Healthcare.

Frequently asked questions